Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 138

Sort by

Sort Order Select

Journal Articles

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)

Cristina Astrid Tentori, Caterina Gregorio, Marie Robin, Nico Gagelmann, Carmelo Gurnari, Somedeb Ball, Juan Carlos Caballero Berrocal, Luca Lanino, Saverio D'Amico, Marta Spreafico, Giulia Maggioni, Erica Travaglino, Elisabetta Sauta, Manja Meggendorfer, Lin-Pierre Zhao, Massimo Bernardi, Carmen Di Grazia, Luca Vago, Giulia Rivoli, Lorenza Maria Borin, Patrizia Chiusolo, Luisa Giaccone, Maria Teresa Voso, Jan Philipp Bewersdorf, Olivier Nibourel, Marina Díaz-Beyá, Andres Jerez, Francisca Maria Hernandez, Kyra Velázquez Kennedy, Blanca Xicoy, Marta Ubezio, Alessia Campagna, Antonio Russo, Gabriele Todisco, Daniele Mannina, Stefania Bramanti, Matteo Zampini, Elena Riva, Marilena Bicchieri, Gianluca Asti, Filippo Viviani, Alessandro Buizza, Benedetta Tinterri, Andrea Bacigalupo, Alessandro Rambaldi, Francesco Passamonti, Fabio Ciceri, Victor Savevski, Armando Santoro, Najla H Al Ali, David A Sallman, Francesc Sole, Guillermo Garcia-Manero, Ulrich Germing, Shahram Kordasti, Valeria Santini, Guillermo Sanz, Wolfgang Kern, Anne Sophie Kubasch, Uwe Platzbecker, Maria Diez-Campelo, Jaroslaw P. Maciejewski, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Amer M. Zeidan, Gastone Castellani, Rami S. Komrokji, Francesca Ieva, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 197.

https://doi.org/10.1182/blood-2023-182194

Published: 2023

Journal Articles

Molecular Classification of Chronic Myelomonocytic Leukemia: Results of the Analysis of an International Cohort of 2,471 Patients

Luca Lanino, Anthony M. Hunter, Claudia Sala, Daniele Dall'Olio, Lorenzo Dall'Olio, Lisa Pleyer, Blanca Xicoy, Manja Meggendorfer, Elisabetta Sauta, Erica Travaglino, Marie Robin, Laura Palomo, David Quintela, Andres Jerez, Elena Cornejo, Paloma Garcia Martin, Marina Díaz-Beyá, Alejandro Avendaño Pita, Veronica Roldan, Dolly Viviana Fiallo Suarez, Estefania Cerezo Velasco, Marisa Calabuig, Giulia Rivoli, Massimo Bernardi, Francesco Onida, Lorenza Maria Borin, Francesco Passamonti, Alessia Campagna, Marta Ubezio, Antonio Russo, Gabriele Todisco, Giulia Maggioni, Cristina Astrid Tentori, Filippo Viviani, Alessandro Buizza, Gianluca Asti, Matteo Zampini, Armando Santoro, Wolfgang Kern, Uwe Platzbecker, Francesc Sole, Maria Diez-Campelo, Angela Consagra, Najla H Al Ali, David A Sallman, Pierre Fenaux, Raphael Itzykson, Michaela Fontenay, Amer M. Zeidan, Rami S. Komrokji, Valeria Santini, Torsten Haferlach, Ulrich Germing, Saverio D'Amico, Gastone Castellani, Eric Solary, Eric Padron, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 3244.

https://doi.org/10.1182/blood-2023-184536

Published: 2023

Journal Articles

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2023) 142 (Supplement 1): 1537.

https://doi.org/10.1182/blood-2023-173302

Published: 2023

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Blood (2023) 142 (Supplement 1): 2011.

https://doi.org/10.1182/blood-2023-180013

Published: 2023

Journal Articles

A D-Dimer and Thrombin Generation-Based Risk Score Predicts Early-Disease Recurrence in a Prospective Cohort of 1,059 High-Risk Breast Cancer Patients

Blood (2023) 142 (Supplement 1): 5460.

https://doi.org/10.1182/blood-2023-186332

Published: 2023

Journal Articles

Roginolisib a Highly Selective Allosteric Modulator of the Phosphoinositide 3-Kinase Delta (PI3Kδ) in Patients with Refractory/Relapsed Follicular Lymphoma

Carmelo Carlo-Stella, Michael Lahn, Tracey Hammett, Paramjit Kaur, Rebeca Zorrilla, Giusy Di Conza, Lars van der Veen, Catherine Pickering, Armando Santoro

Blood (2023) 142 (Supplement 1): 6114.

https://doi.org/10.1182/blood-2023-180671

Published: 2023

Journal Articles

Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study

Muhit Ozcan, Fangfang Lv, Lalita Norasetthada, Ewa Paszkiewicz-Kozik, Joaquin Díaz Schmidt, Dipenkumar Modi, Alexander Fosså, Sagun Goyal, Won Seog Kim, Seung Tae Lee, Armando Santoro, Mehmet Sonmez, Kumudu Pathiraja, Nishitha Reddy, Patricia Marinello, Yuqin Song

Blood (2023) 142 (Supplement 1): 1720.

https://doi.org/10.1182/blood-2023-186788

Published: 2023

Journal Articles

Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study

Blood (2023) 142 (Supplement 1): 3085.

https://doi.org/10.1182/blood-2023-174081

Published: 2023

Journal Articles

Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

Armando Santoro, Nathalie A. Johnson, Kerry J. Savage, Abraham Avigdor, Ali Bazargan, Peter Borchmann, Robin Gasiorowski, Gareth P. Gregory, Yair Herishanu, Sumit Madan, Leonard Minuk, Gerardo Musuraca, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, Pier Luigi Zinzani

Blood (2023) 142 (Supplement 1): 1725.

https://doi.org/10.1182/blood-2023-182536

Published: 2023

Journal Articles

Clinical Text Reports to Stratify Patients Affected with Myeloid Neoplasms Using Natural Language Processing

Blood (2023) 142 (Supplement 1): 122.

https://doi.org/10.1182/blood-2023-188292

Published: 2023

Journal Articles

Synthetic Histopathological Images Generation with Artificial Intelligence to Accelerate Research and Improve Clinical Outcomes in Hematology

Blood (2023) 142 (Supplement 1): 902.

https://doi.org/10.1182/blood-2023-187521

Published: 2023

Journal Articles

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 737.

https://doi.org/10.1182/blood-2023-179169

Published: 2023

Journal Articles

Positron Emission Tomography Evaluation in Relapsed/Refractory B-Cell Lymphoma Patients Treated with Anti-19 Chimeric Antigen Receptor (CAR) T-Cells in the CART-SIE Observational Study

Blood (2023) 142 (Supplement 1): 3517.

https://doi.org/10.1182/blood-2023-184614

Published: 2023

Journal Articles

Combining Gene Mutation with Transcriptomic Data Improves Outcome Prediction in Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 1863.

https://doi.org/10.1182/blood-2023-186222

Published: 2023

Journal Articles

Impact of Daratumumab on Hematopoietic Stem Cell Mobilization with G-CSF and on-Demand Plerixafor in Newly-Diagnosed Multiple Myeloma Patients

Blood (2023) 142 (Supplement 1): 6633.

https://doi.org/10.1182/blood-2023-180082

Published: 2023

Journal Articles

Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma

Armando Santoro, Alison J. Moskowitz, Silvia Ferrari, Carmelo Carlo-Stella, Julie Lisano, Stephen Francis, Rachael Wen, Alev Akyol, Kerry J. Savage

Blood (2023) 141 (22): 2780–2783.

https://doi.org/10.1182/blood.2022017951

Published: 2023

Includes: Supplemental data

Journal Articles

Patients Outcome after Chimeric Antigen Receptor (CAR) T-Cells Failure in Aggressive B-Cell Lymphomas: Role of Immunotherapy and Prognostic Factors

Anna Dodero, Stefania Bramanti, Martina Pennisi, Silva Ljevar, Annalisa Chiappella, Massimo Magagnoli, Anna Guidetti, Francesco Corrado, Paulina Nierychlewska, Alice Di Rocco, Antonello Domenico Cabras, Daoud Rahal, Chiara De Philippis, Armando Santoro, Carmelo Carlo-Stella, Paolo Corradini

Blood (2022) 140 (Supplement 1): 9468–9469.

https://doi.org/10.1182/blood-2022-163651

Published: 2022

Journal Articles

Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

Max S. Topp, Monica Tani, Michael Dickinson, Nilanjan Ghosh, Armando Santoro, Antonio Pinto, Francesc Bosch, Christopher P. Fox, Armando López-Guillermo, Claudia Carlucci, Chun Wu, Kathryn Humphrey, Pauline Baumlin, Martin Barrett, Naseer Qayum, Franck Morschhauser

Blood (2022) 140 (Supplement 1): 1775–1777.

https://doi.org/10.1182/blood-2022-157732

Published: 2022

Journal Articles

PET-Driven Radiotherapy (RT) in Patients with Low Risk Diffuse Large B-Cell Lymphoma (DLBCL): 5-Year Results of the DLCL10 Multicenter Phase 2 Trial By Fondazione Italiana Linfomi (FIL)

Blood (2022) 140 (Supplement 1): 1765–1767.

https://doi.org/10.1182/blood-2022-159759

Published: 2022

Journal Articles

Decisional Role of Interim PET in Relapsed/Refractory Classical Hodgkin Lymphoma Treated with Begev Chemotherapy As First Salvage

Chiara Rusconi, Francesca Ricci, Vincenzo Marasco, Vittorio Ruggero Zilioli, Eleonora Calabretta, Anna Guidetti, Cristina Muzi, Federico Mazzon, Margherita Smania, Martina Sollini, Sara Iadecola, Erika Meli, Marcello Rodari, Emanuele Ravano, Roberto Cairoli, Paolo Corradini, Armando Santoro

Blood (2022) 140 (Supplement 1): 6581–6583.

https://doi.org/10.1182/blood-2022-165948

Published: 2022

NARROW

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)

Molecular Classification of Chronic Myelomonocytic Leukemia: Results of the Analysis of an International Cohort of 2,471 Patients

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

A D-Dimer and Thrombin Generation-Based Risk Score Predicts Early-Disease Recurrence in a Prospective Cohort of 1,059 High-Risk Breast Cancer Patients

Roginolisib a Highly Selective Allosteric Modulator of the Phosphoinositide 3-Kinase Delta (PI3Kδ) in Patients with Refractory/Relapsed Follicular Lymphoma

Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study

Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study

Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

Clinical Text Reports to Stratify Patients Affected with Myeloid Neoplasms Using Natural Language Processing

Synthetic Histopathological Images Generation with Artificial Intelligence to Accelerate Research and Improve Clinical Outcomes in Hematology

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Positron Emission Tomography Evaluation in Relapsed/Refractory B-Cell Lymphoma Patients Treated with Anti-19 Chimeric Antigen Receptor (CAR) T-Cells in the CART-SIE Observational Study

Combining Gene Mutation with Transcriptomic Data Improves Outcome Prediction in Myelodysplastic Syndromes

Impact of Daratumumab on Hematopoietic Stem Cell Mobilization with G-CSF and on-Demand Plerixafor in Newly-Diagnosed Multiple Myeloma Patients

Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma

Patients Outcome after Chimeric Antigen Receptor (CAR) T-Cells Failure in Aggressive B-Cell Lymphomas: Role of Immunotherapy and Prognostic Factors

Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

PET-Driven Radiotherapy (RT) in Patients with Low Risk Diffuse Large B-Cell Lymphoma (DLBCL): 5-Year Results of the DLCL10 Multicenter Phase 2 Trial By Fondazione Italiana Linfomi (FIL)

Decisional Role of Interim PET in Relapsed/Refractory Classical Hodgkin Lymphoma Treated with Begev Chemotherapy As First Salvage

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only